On Tuesday, Stifel adjusted its price target on shares of Medtronic , Inc. (NYSE:MDT), increasing it to $87.00 from the previous $85.00, while maintaining a Hold rating on the stock. The firm acknowledged Medtronic's consistent mid-single-digit revenue growth over the last seven quarters, noting the company's positive strides in its innovation pipeline.
Medtronic's recent financial report for the first quarter of fiscal year 2025, covering May to July, showed sales amounting to $7.915 billion, a 5.3% organic increase, which surpassed both Stifel's and the consensus estimate of $7.89 billion.
This outperformance was attributed in part to the company's Cardiac Rhythm Management products. Earnings per share (EPS) for the quarter came in at $1.23, exceeding the anticipated $1.20 by Stifel and consensus, with the beat credited to a lower-than-expected share count and strong top-line performance.
Despite foreign currency headwinds that constrained earnings growth to around 3% year-over-year, Medtronic conveyed optimism that these pressures would lessen in the second half of fiscal year 2025, spanning from November to April. The company's pipeline developments, such as the Affera cardiac ablation system, which is currently under FDA review, and the HUGO robotic surgery system, which has reached its target enrollment for the FDA urology indication trial, were highlighted as positive indicators.
Additionally, Medtronic is engaged in ongoing discussions regarding renal denervation reimbursement, with the company's management viewing these conversations as moving in a favorable direction. Despite the modest earnings beat for the quarter, Medtronic's management has conservatively increased its full-year 2025 EPS guidance by only $0.01 at the midpoint.
In other recent news, Medtronic Inc (NYSE:MDT). has seen a series of financial developments. The medical device manufacturer reported first-quarter non-GAAP revenue of $8.00 billion and earnings per share (EPS) of $1.23, surpassing anticipated figures.
This led the company to update its fiscal year 2025 organic sales growth forecast to 4.5-5% and refine its EPS guidance to $5.42-$5.50. Medtronic also announced a quarterly cash dividend of $0.70 per ordinary share for the second quarter of fiscal year 2025, continuing its streak of increasing annual dividend payments.
In terms of analyst ratings, TD Cowen has maintained its Buy rating for Medtronic, while Stifel downgraded the company from Buy to Hold. UBS upgraded the company's stock from Sell to Neutral, citing renewed confidence in the Diabetes business segment. These ratings changes reflect different perspectives on the company's future growth potential.
Medtronic has also seen developments in its product offerings. The company has received FDA approval for its new Simplera™ continuous glucose monitor (CGM) and announced a partnership with Abbott to expand CGM options for individuals with diabetes.
This collaboration is expected to positively contribute to the company's Diabetes revenue. These are the recent developments in Medtronic's financial performance, analyst ratings, and product offerings.
InvestingPro Insights
In the context of Medtronic's recent financial performance and Stifel's updated price target, certain metrics and InvestingPro Tips offer additional insights. Medtronic's management has demonstrated confidence in the company through aggressive share buybacks and a commendable track record of raising its dividend for 10 consecutive years, with dividend payments maintained for an impressive 48 years. These actions suggest a stable and shareholder-friendly financial policy. Notably, the company's stock trades with low price volatility, which may appeal to investors seeking consistency in their portfolio.
From a valuation standpoint, Medtronic is trading at a P/E ratio of 30.83, which is above the industry average indicating a high earnings multiple. However, looking at the last twelve months as of Q4 2024, the adjusted P/E ratio shows a more moderate figure at 22.97. The company's revenue growth over the same period was 3.64%, reflecting steady progress in a competitive healthcare equipment and supplies industry. Medtronic's gross profit margin at 65.73% underscores its ability to maintain profitability, and with a dividend yield of 3.3%, the stock may be attractive for income-focused investors.
For those interested in further analysis, InvestingPro offers additional tips on Medtronic, including insights into the company's future profitability and analyst predictions. With a fair value estimated at $90.5 by InvestingPro, the stock is currently trading near its 52-week high, which could signal market confidence in its growth trajectory. For a deeper dive into Medtronic's financial health and stock performance, investors can explore more than nine additional InvestingPro Tips available at https://www.investing.com/pro/MDT.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.